3KUMAR N,DEY C S.Development of insulin resistance and reversal by Thiazolidineiones in C2C12 skeletal muscle cells[J].Biochem Pharmacol,2003,65:249-257.
4PORTER L E,FREAD M I,JONES N P,et al.Rosiglitazone im.Proves cellfunction as measured by proinsulin insulin ratio in patients with type 2 diabetes[J].Diebetes,2000,49(Suppl 1):A122.
1[1]UK Prospective Diabetes Study(UKPDS)Group Intentive blood glucose control with sulphonylureas or insulin compared with conventional treatment ang risk of complication in patients with type 2 diabetea(UKPDS33).Lanct 1998;352:837.
2[2]Spiegelman BM.PPAR-gamma:adpogenic regulator and thiazolidinedione receptor.Diabetes 1998;47:507-514.
3[4]Smith SA,Cawthorne MA,Coyle PJ,et al.BRI.49653normalises glycaemic control in.Zucker fa/fa rats by improving hepatic and peripheral tissue sensitivity to insulin.Diabetologia 1993;36:184-211.
3WOLF G,CHEN S,ZIYADEH F N.From the periphery of glumeruLar capillary wall toward the center of disease:podocyte injury comes of age in diabetic nephropathy[J].Diabetes,2005,54(6):1626-1634.
4TUTTLE K R.Protein kinase C-beta inhibition for diabetic kidney disease[J].Diabetes Res Clin Pract,2008,82(3):70-74.
9Wang CZ ,Pan X. Profile of vildagliptin in type 2 diabetes : efficacy, safe- ty, and patient acceptability. Therapeutics Clinical Risk Management, 2013,20:247-257.
10Kumar G, Kumar J, Khan FA, et al. The serum C Peptide levels among the offsprings of the people with type 2 diabetes. Journal of clinical and diagnostic research: JCDR,2013 ,7 :827-830.
